Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Conditions:   Irritable Bowel Syndrome With Constipation;   Functional Constipation Interventions:   Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers);   Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers): Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Irritable Bowel Syndrome With Constipation;   Functional Constipation Interventions:   Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers);   Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers): Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Purpose of review There is growing evidence encouraging the use of probiotics in many conditions in children. However, given the wide number of probiotics available and contradictory data in the literature, the health-care provider is often faced with uncertainness about whether or not to use probiotics and which one(s) to choose. We here review current hypotheses regarding the efficacy and safety of probiotics and evaluate the available data on the use of probiotics in most common diseases in children. Considering that probiotics have strain-specific effects, we will focus on individual probiotic strains rather than on ...
Source: Current Opinion in Pediatrics - Category: Pediatrics Tags: GASTROENTEROLOGY AND NUTRITION: Edited by Bradley Barth Source Type: research
Authors: Geijo Martínez F, Sánchez Garrido A, Marcos Prieto H, Piñeiro Pérez C, Prieto Bermejo AB, Álvarez Delgado A, Velasco Guardado A, Rodríguez Pérez A Abstract BACKGROUND: constipation-predominant irritable bowel syndrome (C-IBS) is a prevalent, complex and multifactorial disorder that represents a challenge in terms of diagnosis and therapeutic management. OBJECTIVE: to evaluate the effectiveness, safety and treatment satisfaction of linaclotide in C-IBS patients. METHODS: prospective, single-center and observational study conducted in patients diagnose...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
Date: April 24, 2017 Issue #:  1519Summary:  The FDA has warned that eluxadoline (Viberzi– Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with diarrhea (IBS-D),1 should not be used in patients without a gallbladder because of an increased risk of serious pancreatitis.2As of February 2017, the FDA had received reports of 118 cases of serious, nonfatal pancreatitis and 2 deaths associated with use of eluxadoline. Both deaths occurred in patients without a gallbladder who developed severe abdominal pain ...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Alosetron Diarrhea Drug Safety eluxadoline Imodium irritable bowel syndrome Loperamide Lotronex Rifaximin Viberzi Xifaxan Source Type: research
Abstract Non‐IgE‐mediated gastrointestinal food allergic disorders (non‐IgE‐GI‐FA) including food protein‐induced enterocolitis syndrome (FPIES), food protein‐induced enteropathy (FPE), and food protein‐induced allergic proctocolitis (FPIAP) are relatively uncommon in infants and young children, but are likely under‐diagnosed. Non‐IgE‐GI‐FA have a favorable prognosis, with majority resolving by age 3–5 years. Diagnosis relies on the recognition of symptoms pattern in FPIAP and FPIES and biopsy in FPE. Further studies are needed for a better understanding of the pathomechanism, which will lead ...
Source: Pediatric Allergy and Immunology - Category: Allergy & Immunology Authors: Tags: Review Article Source Type: research
Dr. Dascha Weir, associate director, Boston Children’s Celiac Disease Program It may be difficult for parents to hear that their child has a chronic illness. When the diagnosis is celiac disease (CD), an autoimmune disorder caused by an intolerance to gluten, there is good news. CD is treatable by changes in diet. How it works: When food enters the stomach, it’s broken down into tiny digestible particles, which then travel through the small intestine. The small intestine is lined with villi — tiny finger-like projections that absorb nutrients from the food passing through. In celiac disease...
Source: Thrive, Children's Hospital Boston - Category: Pediatrics Authors: Tags: Diseases & Conditions celiac disease Dr. Dascha Weir gluten intolerance Source Type: news
By Cynthia Sass, MPH, RD Suspect you might have a sensitivity to gluten or dairy, but aren't sure which is the culprit? You might be considering trying an elimination diet. This short-term eating plan has gained popularity recently as a way to identify potential food issues, including allergies, intolerances, and triggers of irksome symptoms--from bloating, joint pain, and fatigue to skin issues like eczema. While there's no one-size-fits-all protocol, an elimination diet typically involves two phases. In the first, several foods are eliminated for at least four weeks, sometimes eight. Then, those foods are added back, o...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
This article is protected by copyright. All rights reserved.
Source: Pediatric Allergy and Immunology - Category: Allergy & Immunology Authors: Tags: Review Source Type: research
ConclusionsThe overall work productivity impairment as a result of nocturia is substantial and was found to be similar to impairment observed as a result of several other more frequently researched common chronic diseases. Greater awareness of the burden of nocturia, a highly bothersome and prevalent condition, will help policy makers and healthcare decision makers provide appropriate management of nocturia.
Source: PharmacoEconomics - Category: Health Management Source Type: research
CONSTELLA® is the only available prescription treatment with a European Marketing Authorisation specifically for irritable bowel syndrome with constipation
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Gastroenterology Patient care constella constipation IBS-C irritable bowel syndrome Latest News marketing authorisation Source Type: news
More News: Allergy | Constipation | Irritable Bowel Syndrome | Pediatrics | Research